These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34192881)

  • 1. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
    Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
    J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease.
    Lichtenstein GR; Soonasra A; Latymer M; Singh S; Feagan BG
    Expert Opin Biol Ther; 2024 Jul; 24(7):691-708. PubMed ID: 38979696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration.
    Patel S; Walsh J; Pinnell D; Pei S; Chen W; Rojas J; Rathod A; Johnson J; Gawron A; Curtis JR; Baker JF; Cannon GW; Wu D; Lai M; Sauer BC
    Medicine (Baltimore); 2024 Sep; 103(37):e39476. PubMed ID: 39287304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series.
    Rosenthal B; Aulakh S; Patel PV; Wong JT; Ali S
    Am J Health Syst Pharm; 2024 Jan; 81(2):61-65. PubMed ID: 37773728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
    Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
    Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
    Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
    J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease.
    O'Connell DM; Nachreiner J; Shu X; Terry E; Imburgia T; Vanderloo J; Lasarev MR; Bogenschutz M
    J Pediatr Gastroenterol Nutr; 2022 May; 74(5):605-609. PubMed ID: 35149648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
    Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
    Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
    Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
    Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis.
    Deaner JD; Srivastava SK; Hajj-Ali RA; Lowder CY; Venkat AG; Baynes K; Sharma S
    Am J Ophthalmol; 2021 May; 225():172-177. PubMed ID: 32795432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar infliximab use in paediatric IBD.
    Richmond L; Curtis L; Garrick V; Rogers P; Wilson M; Tayler R; Henderson P; Hansen R; Wilson DC; Russell RK
    Arch Dis Child; 2018 Jan; 103(1):89-91. PubMed ID: 28988215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.